Bringing together the UK’s life sciences companies and investors
Investor funding is the lifeblood of the life sciences sector. So how will investment be affected during the current COVID-19 crisis, particularly in SME’s and start-ups seeking operating or growth capital? The simple answer is … very significantly!
A changing capital environment - most company founders are probably unaware as to how much the capital raising environment has changed in a very short time. When the markets drop 30+% in 3 weeks, many things change and leveraging necessary investment becomes much harder. Investors are nervous about moving cash around in the current environment particularly since for many their current investments have just been dramatically marked down in terms of value
Investor shock - most funders are holding their investments and waiting for recovery, rather than liquidating at a much lower value and then reinvesting. For those holding private investments, attempting to recoup cash from balance sheets will be extremely tough
Liquidity challenges - in this challenging environment, the risk of small companies simply running out of operating capital because they fail to fund-raise adequate amounts in sufficient time cannot be underestimated
Lack of investor-investee contact - interaction with potential investors will also become more difficult. Currently, most investors generate much of their deal flow from direct contacts made at credible pitching events (~60%) and this is a route that is being cut off, and this is likely to be the case for the foreseeable future
OBN Ventures (OBNV) offers a solution to these problems. It is a major funding initiative that is designed to help alleviate these issues and enable companies to access the liquidity they need to continue to function and grow during this time.
WHY USE OBN VENTURES?
¬ Simple online application process
¬ Manage your deal listing through an easy-to-use interface
¬ Upload promotional materials including images, videos and team profiles and confidential documents in a secure data room
¬ Track investor interest in your deal with real-time analytics
¬ Control who views your documents with tiered information access
¬ Interact with investors using in-built Q&A facilities
¬ Gain exposure to a 6,000+ professional investors
¬ Accept pledges and transact through the platform
¬ Keep shareholders up-to-date with investor relations portal
¬ Platform use is compatible with EIS/SEIS Tax Relief but the associated responsibilities lie with companies
¬ Sign-up and self-certify online in minutes
¬ Browse investment opportunities from across the UK 24/7
¬ Find your ideal investment opportunity using advanced deal filtering
¬ Shortlist opportunities and monitor company progress with deal tracking and automatic updates
¬ Conduct due diligence online with immediate document access
¬ Engage with management teams using Q&A facilities
¬ Set-up founder one-on-one intros at a single click
¬ Pledge and transact online
¬ Build and monitor your portfolio from a single easy-to-access location
¬ Receive shareholder updates through the system
OBN Ventures in brief
OBN Ventures Ltd (OBNV) is a wholly owned subsidiary of OBN (UK) Ltd, and offers a sophisticated FCA-approved on-line investment platform which is designed to bring a wide range of professional investors together with early-stage life sciences and related companies that in some instances are yet to achieve any revenues and in the majority of cases will not have reached the point of profitability.
This platform is totally complementary in approach with OBN’s major investment conferences (BioTrinity® and BioSeed®) and offers the advantages of leveraging a wider range of investors and availability on a year-long basis.
OBNV’s core strategy is to focus on early stage life sciences companies with strong intellectual property (‘IP’), and the potential for growth to £100m+ valuations or more, where the added value of OBNV/OBN may offer distinct advantage to investee companies.
If you have questions about OBN Ventures that are not covered by the materials on this site please contact John Harris, Investment Director of OBN Ventures and CEO of OBN (UK) Ltd.
OBN Ventures, a subsidiary of OBN, aims to bring together investors and early stage UK life sciences companies to accelerate growth and success. OBN is the not-for-profit Membership organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Our 400-plus Member companies are located across the Golden Triangle and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland, benefiting from our networking, partnering, purchasing, training, advising and advocacy activities.
The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. OBN Ventures Limited does not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.Please click here to see the full Risk Warning.